The Food and Drug Administration has given Viatris permission for iron sucrose injection, an intravenous iron replacement product used to treat iron deficiency anemia in adult and pediatric patients ...

Viatris (NASDAQ:VTRS) announced on Monday that the U.S. FDA has approved its Iron Sucrose Injection, USP, as a generic product targeting Venofer marketed by Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) ...

Viatris Inc (NASDAQ:VTRS) saw its stock increase by 2.6% after the U.S. Food and Drug Administration approved its Iron Sucrose Injection, USP, marking the first generic alternative to Venofer® ...

Amphastar has received permission from the Food and Drug Administration for iron sucrose injection, 50mg/2.5ml, 100mg/5ml and 200mg/10ml in single-dose vials, previously referred to as AMP-002. Iron ...

Viatris and Amphastar Pharmaceuticals both received Food and Drug Administration approval of generic iron sucrose injection products for the treatment of iron deficiency anemia in patients with ...

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s AMPH Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, 100mg/5mL, ...

All 3 strengths of iron sucrose injection are expected to be available “imminently”. The Food and Drug Administration (FDA) has approved the first generic version of Venofer ® (iron sucrose) Injection ...

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Viatris Inc. is one of them. Viatris Inc. (NASDAQ:VTRS), formed from the 2020 merger of Mylan ...